Abstract Until recently, chemotherapy for visceral leishmaniasis (VL; also known as kala-azar) was severely limited by factors such as high cost, route of administration, generation of side effects and potential for resistance.
Introduction
Many Leishmania parasites are pathogenic for humans and an estimated 2 million cases occur each year. There are approximately 350 million people in Leishmaniaendemic areas, although the geographic distribution of each Leishmania species affects the clinical manifestations and type of disease [1, 42] . Visceral leishmaniasis (VL; also known as kala-azar) is caused by L. donovani in South Asia and Africa, while L. infantum causes VL in the Mediterranean, the Middle East, Latin America and parts of Asia [1, 42] . VL is characterized by an infection of the reticuloendothelial system (RES; spleen, bone marrow and liver) and presents as a systematic inflammatory condition. If left untreated, VL is fatal within months in virtually all symptomatic patients and even when successfully treated, post-kala-azar dermal leishmaniasis (PKDL) can occur.
The pentavalent antimonials such as sodium stibogluconate (SSG) and meglumine antimoniate have been widely used to treat leishmaniasis for over 70 years, but resistance to these drugs is increasing [33, 37] . Although previously hampered by factors such as high cost, toxicity or route of administration [25] , various chemotherapies and additional drugs that are largely effective for the treatment of leishmaniasis are either now available or are being developed [26, 33, 35, 36, 39] . Novel therapeutic strategies are also being developed for leishmaniasis to provide more cost-effective and tolerable treatment [38] . Treatment strategies have typically investigated parasite burden as a measure of treatment efficacy, requiring invasive procedures such as bone marrow aspiration to collect pertinent samples. The further emergence of improved treatment regimen could be aided by the identification of additional biomarkers that are altered upon successful treatment [27] .
The identification of relatively simple serological parameters would both simplify sample collection and expedite analyses of multiple samples. Particular biomarkers that are indicative of the severity of VL disease could be used to aid therapeutic prognosis and, if necessary, guide changes in treatment. Although circulating antibodies can and have been used to regulate entry into clinical trials, multiple lines of investigation indicate that anti-leishmanial antibodies can persist even after successful treatment with chemotherapy and are, therefore, not appropriate as surrogate indicators of cure [14, 15, 20, 21, 24, [28] [29] [30] 34] . Other biomarkers indicative of the cellular immunological response to VL disease have been shown to reflect the severity of disease progression and could be useful as markers of recovery following therapy [8] . With regard to the cellular immune response, active VL is characterised by a negative delayed type hypersensitivity (skin test) for parasite antigens and failure to produce Th1 cytokines and IL-10 is well documented as the predominant cytokine during active VL [4, 13, 17, 18] . Conversely, the protective immunity of VL patients successfully cured by chemotherapy is associated with cell-mediated responses represented by the production of Th1 cytokines like IFNγ and IL-2 upon antigen recall [3, 5] .
In this study, we assessed various inflammatory cytokines, chemokines and growth factors to generate an extensive immunological profile of VL patients infected with different Leishmania species and in different regions. We hypothesized that the serum levels of some inflammatory mediators would rise, and, concomitantly, some anti-inflammatory mediators would decrease, during successful intervention, and tested this hypothesis by assessing the effect of standard meglumine antimoniate treatment on various circulating markers. Our results identify several markers that, when used in conjunction, could facilitate the evaluation of new VL treatments.
Materials and methods

Study participants
A total of 76 newly diagnosed, previously untreated VL patients were recruited at either the Rajshahi Medical College Hospital, Rajshahi, Bangladesh and Hospital Universitário, Universidade Federal de Sergipe, Aracaju, Brazil. All VL patients were given complete clinical evaluations at the time of recruitment and were provided treatment. Healthy endemic controls (EC) were also recruited in each site. As further controls in Bangladesh, asymptomatic individuals were recruited by positive response in the k39 rapid test. As further controls in Brazil, individuals with Chagas disease, tuberculosis and Dengue fever were recruited, as were individuals presenting with enlarged livers but who were negative by the k39 rapid test (Table 1) . Immune compromised individuals were excluded. Samples were also collected from a cohort of Brazilian VL patients at regular times throughout and after treatment with meglumine antimoniate (20 mg/kg for 20 days). Blood was collected by venipuncture, sera prepared and stored at −20°C until assay. The study component in Bangladesh was approved by both the icddr and Rajshahi Medical College ethical review committees, and the study component in Brazil was approved by local and national ,000 pg/ml) or purchased from Affymetrix (Fremont, CA, USA; MPO, MMP-1, MMP-9, sICAM-1 and sVCAM-1; each analyte was detected over a range of 6.7-400,000 pg/ml). Assays were performed according to the manufacturer's instructions. Briefly, samples were diluted and incubated with anti-target coated magnetic beads. After washing, beads were incubated with detection antibodies, washed again, then incubated with streptavidin-phycoerythrin. After final washes, phycoerythrin incorporation onto bead was measured by reading on a Luminex 200 and concentration data were generated using MasterPlex® QT software (MiraiBio Group, South San Francisco, CA, USA).
Parasite detection by PCR
Blood samples were shipped in Paxgene collection tubes containing 6.9 ml Paxgene and 2.5 ml blood. Prior to extraction, 200 ng of a non-homologous linearised DNA segment was added as an internal standard (IS) to regulate extraction efficiency [10] . Tubes were centrifuged, then the pellets washed twice with nuclease-free dH 2 O, and DNA extracted using the QIAamp DNA Mini Kit (Qiagen, Frederick, MD, USA). Real-time polymerase chain reaction (PCR) amplification of Leishmania DNA was conducted on a Roche LightCycler 480 (Roche, Pleasanton, CA, USA) using ABI TaqMan primers and probes targeting the conserved region of the Leishmania 18S ribosomal RNA gene [accession number X0773.1; 5′-CCGTTTCG GCTTTTGTTGGTTTTAA; GCGATGGGAAAGCACT TGTC-3′; and reporter (FAM): CAGCTCCATAATCT CC] [32] . Each sample was originally examined in duplicate, and samples that did not amplify, or had very late amplification, were re-evaluated in triplicate. Samples were semi-quantified by assigning them a threshold cycle (Ct) when DNA was amplified, and were arbitrarily assigned a Ct of 55 cycles when no amplification occurred.
Statistical analyses
Exploratory data analysis, including box plot and scatter plot, medians and interquartile range (IQR) were used to analyse the analyte levels among the different study groups. Statistical significance was assessed by Kruskal-Wallis one-way analysis of variance (ANOVA), followed by Dunnett's multiple comparison test (GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, CA, USA). Results were considered statistically significant when pvalues<0.05 were obtained.
Results
Th1/Th2 cytokine profile of VL patients
The Th1-associated cytokines IL-12 and IFNγ are well known to be associated with clearance of Leishmania parasites and clinical cure, while Th2 cytokines inhibit the protective response and can exacerbate disease [2-5, 13, 17, 18] . Of the analytes measured, the Th1-associated cytokines IFNγ, IL-12p40 and IL-12p70 gave the clearest discrimination of patients from control samples ( Fig. 1 and Supplemental Figure 1 ). While low to undetectable levels were observed in all control groups in both Bangladesh and Brazil, cytokine levels above 50 pg/ml were found in the serum of 60 % and 67 % (IFNγ), 63 % and 75 % (IL-12p40) and 37 % and 38 % (IL-12p70) of Bangladeshi and Brazilian VL patients, respectively. Somewhat paradoxically, Th2 cytokines were also found to be circulating in the sera of minor subsets of VL patients but not controls ( Fig. 1 and Supplemental Figure 1 ). Most notably, IL-4 was detected at over 50 pg/ml in the serum of 17 % of Bangladeshi VL patients and 29 % of Brazilian VL patients, while IL-13 was above this threshold in 17 % and 21 % of these VL patients, respectively.
The analysis of regulatory cytokines also revealed significant differences between VL patients and controls ( Fig. 1 and Supplemental Figure 1 ). IL-10 was detected at median levels of 159 and 353 pg/ml in VL patients, such that 83 % and 92 % of Bangladeshi and Brazilian patients had circulating serum levels greater than 50 pg/ml, respectively. Serum IL-17 was detected above 50 pg/ml in 53 % and 50 % of these VL patients, respectively.
Inflammatory cytokine profile of VL patients
The most striking difference in pro-inflammatory cytokine levels in the Brazilian VL population could be observed for TNFα, where 83 % of VL patients (20 of 24) had circulating levels above 50 pg/ml, in contrast with only a single tuberculosis patient that fit this criterion within the control groups (Fig. 2) . VL patients presented with elevated circulating IFNα2 levels in comparison with controls (Fig. 2) . In Bangladesh, circulating IFNα2 levels were greater than 75 pg/ml in 50 % of VL patients and in Brazil, 67 % of VL patients were above this threshold. In contrast, all control groups had fewer than 8 % of recruits presenting with IFNα2 above 75 pg/ml.
The analysis of samples from Bangladesh indicated that IL-1α was above 50 pg/ml in the serum of a subset of VL patients (50 %, 15 of 30) and asymptomatic individuals (35 %, 6 of 17) (Fig. 2) . A subset of healthy Bangladeshi controls (4 of 10, 40 %), however, also fit this criterion. This general observation held true among the samples from Brazil, with IL-1α levels above 50 pg/ ml in 50 % of VL patients (12 of 24). Similar patterns, albeit at lower levels and reduced overall proportion, were observed for circulating IL-6 in both Bangladeshi and Brazilian groups (Supplemental Figure 1) . IL-1β and TNFβ were virtually undetectable, while TGFα was found constitutively in all groups, such that these 
Growth factor profile of VL patients
A number of growth factors were affected by Leishmania infection (Fig. 3 and Supplemental Figure 2 ). Not surprisingly, the T cell growth factors IL-2 and IL-15 were found to be circulating in the blood of VL patients but were absent in controls (Fig. 3) . The hematopoietic growth factor, Flt3L, was similarly found to be elevated in the sera of VL patients, as were vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF2) (Fig. 3 and Supplemental Figure 2 ). GM-CSF was increased in the sera of Brazilian VL patients versus the negligible levels in the sera of Brazilian controls, although it was present in the sera of all Bangladeshi volunteers such that a difference between VL patients from controls could not be discerned in that population. IL-3, EGF and G-CSF (Supplemental Figures 1 and 2) were not significantly different between VL and EC in either country.
Chemokine profile of VL patients
We also examined a number of chemokines to determine if they could distinguish VL patients from controls (Supplemental Figure 3) . The sole chemokine analysed that demonstrated significant differences between VL patients and EC was CXCL10, although this difference was only noted in the Brazilian population.
Various biomarkers are reduced during treatment
Taken together, our data indicate a variety of serum biomarkers found at levels in VL patients distinct from those observed during other diseases and in healthy individuals. We hypothesised that many of these biomarkers would be altered during the course of antileishmanial treatment. To identify which markers were affected, and how rapidly, sera were collected at regular intervals from a cohort of patients undergoing chemotherapy with meglumine antimoniate. Several cytokines were rapidly reduced following the initiation of treatment (Fig. 4 and Supplemental Figure 4) . Of all the analytes examined, IL-10 was the most rapidly reduced, falling to 20 % of the time of diagnosis levels by 2-3 weeks of treatment and continued to decline to undetectable levels 6 months after treatment (Fig. 4b) . TNF and IFNγ levels were also notably diminished during treatment, with both of these inflammatory cytokines reduced by approximately 50 % by 2-3 weeks of treatment (p -values<0.05 versus time of diagnosis). IL-1rα, sIL-2Ra and FGF2 followed a similar decline during treatment (Supplemental Figure 4) .
Some biomarkers increase or are not altered during treatment
In contrast to those markers that declined upon treatment, a handful of markers were unaffected and some actually increased ( Fig. 5 and Supplemental Figure 4 ). The most obviously increased was sCD40L, although MPO and MMP9 were also significantly increased at various times after treatment (Fig. 5 ). sCD40L and MMP9 were significantly increased as early as 2 weeks after the initiation of treatment, whereas MPO required 6 months to demonstrate statistically significant elevations.
Correlation of biomarkers with circulating Leishmania DNA DNA was extracted from several blood samples in order to semi-quantify circulating parasite DNA. As expected, and consistent with data generated from samples obtained during therapy, parasite DNA levels were highest in the samples that demonstrated the highest concentrations of IL-10, sIL-2Ra, TNF, IL-6 and IFNγ, and the lowest concentrations of MMP9 (Fig. 6 ). As anticipated, circulating Leishmania DNA levels were reduced by treatment (Fig. 7) . Taken together, our data identify several circulating biomarkers whose concentrations appear to be linked to the magnitude of Leishmania infection.
Discussion
Novel therapeutic strategies are being developed for VL to provide more cost-effective and tolerable treatment. These strategies have typically investigated parasite burden as a measure of treatment efficacy, requiring invasive procedures such as bone marrow aspiration to collect pertinent samples. The use of relatively easy to obtain serological parameters could simplify sample collection, facilitate expeditious analyses of multiple samples and accelerate trials of new treatments [27] . By analysing the levels of various chemokines and cytokines in the serum at the time of initial diagnosis, we established an immune profile that distinguished VL patients from healthy individuals and those with other diseases. Furthermore, we identified markers whose concentrations correlated with circulating Leishmania DNA (which is likely reflective of parasite burden) and demonstrated that these are changed by treatment. It has previously been reported in various settings that VL patients exhibit mixed Th1/Th2 responses and present with elevated levels of circulating IFNγ, TNFα, IL-1, IL-6 and IL-10, and our results corroborated these findings [6-8, 16, 33, 40] . We also noted that IL-17 was elevated in subsets of VL patients in both regions, Fig. 4 Reductions in serum cytokines during anti-leishmanial treatment. Plasma were collected from clinically diagnosed VL patients in Brazil at the time of diagnosis and at various times during or after treatment (20 mg meglumine antimoniate/kg for 20 days). In A, total levels are plotted on the y-axis and time relative to the initiation of treatment is indicated on the x-axis. In B, biomarker levels at each time point were normalised versus the value obtained from the same patient's intake sample (time of diagnosis or within the first week after the initiation of treatment). Time relative to the initiation of treatment is indicated on the x-axis: days 0-7, n =46; days 14-21, n =40; 1 month, n =35; 1.5 months, n =31; 2 months, n =30; 6 months, n =7; and 12 months, n =3. *=p-value<0.05 versus time of diagnosis further demonstrating the complexity of the response, which involves inflammatory and immune regulatory molecules. In both of our study sites, IL-10 was found at elevated levels in the circulation of the greatest proportion of VL patients. It is noteworthy that high IL-10 levels have also been recently shown to correlate with high parasite burden in Indian VL patients [41] . Again, our results are in agreement with this observation, although, in addition, we found that IL2Ra, IL-6 and IFNγ levels also correlated with circulating Leishmania DNA among Brazilian VL patients. Of note, we observed differences between the naturally circulating levels of several markers, including IL-6, between Bangladeshi and Brazilian subjects. The reasons for these differences are unclear, but it is possible that different genetic makeups of the hosts and pathogens, or environmental stimuli, could contribute to this discrepancy.
Identifying and differentiating biomarkers that are altered as a result of infection, active disease or secondary symptoms is difficult. IL-10 and sIL-2Ra were readily measured in the sera of non-VL patients with enlarged livers, while circulating IFNγ and FGF2 were not. These data, therefore, suggest that IL-10 and sIL-2Ra might be more closely associated with symptoms than Leishmania infection. Hepatocytes can produce IL-10 that can limit naive CD4 T cell activation and IL-10 can limit fibrosis [19, 31] . Thus, although clearly linked with controlling the anti-Leishmania immune response, the primary role of IL-10 and the reason for its high circulating levels may be attempts at preserving liver function. It has previously been Plasma were collected from clinically diagnosed VL patients in Brazil at the time of diagnosis and at various times during or after treatment (20 mg meglumine antimoniate/kg for 20 days). In A, total levels are plotted on the y-axis and time relative to the initiation of treatment is indicated on the x-axis. In B, biomarker levels were also normalised versus the mean value obtained from samples obtained at the time of diagnosis or within the first week after the initiation of treatment. Time relative to the initiation of treatment is indicated on the x-axis: days 0-7, n =46; days 14-21, n =40; 1 month, n =35; 1.5 months, n =31; 2 months, n =30; 6 months, n =7; and 12 months, n =3. *=p-value<0.05 versus time of diagnosis reported that sIL-2Ra declines rapidly during 30-day treatment with SSG, and patients with the highest sIL2Ra levels may be predisposed to develop PKDL [12] . Our data support the use of declining sIL-2Ra levels as a measure of improving liver condition during VL therapy, but the current study was not sufficiently powered to draw links with PKDL incidence. We recently reported that Brazilian VL patients present with low sCD40L levels in their circulation in contrast with the high levels observed in endemic controls [9] . In Bangladesh, sCD40L levels were indistinguishable between VL patients and endemic controls, although, interestingly, asymptomatic individuals had elevated plasma concentrations. This may reflect differing Leishmania infectivity rates or may be influenced by the different pathogen compositions of these regions. The levels of sCD40L and MMP9 both demonstrated a continual rise Fig. 6 The relationship of circulating Leishmania DNA levels with biomarker concentration. Circulating parasite DNA levels were established within samples by real-time polymerase chain reaction (PCR), and these are plotted versus relative levels of the indicated biomarkers within matching plasma. An arbitrary threshold of 55 was assigned for PCR-negative samples, with the solid line representing the best-fit linear regression and the dashed lines representing the 95 % confidence intervals throughout the treatment of Brazilian patients. These alterations are consistent with the reported observation that sCD40L can trigger increases in MMP9 production but are somewhat in conflict with a report that in vitro infection of human macrophages with L. braziliensis increases the secretion and activation of MMP9 [22] . It is known that neutrophils can enhance the release of sCD40L, which is produced by platelets. It is, therefore, noteworthy that neutrophil depletion can lead to an increase in L. donovani parasite growth following experimental infection [23] , and that perturbations in other neutrophil functions have previously been noted in VL patients [11] . How the levels of IL-17, which contributes to neutrophil development, are impacted remains unclear. Regardless, these data suggest that the reduced levels of sCD40L during active L. donovani infection may be a function of parasite-induced perturbation of neutrophils. This hypothesis remains to be proven.
Among the greatest challenges for the development of new intervention schemes for VL is expedient evaluation of candidate strategies, particularly when long periods of time are required to generate data relating to clinical outcome. Determining the immunological profiles that are associated with ongoing or cured VL is valuable for evaluating chemotherapeutic or immunological strategies to treat or prevent VL. Our results provide further evidence of an immune signature associated with VL and identify parameters that change upon successful treatment. 
